First Drug to Slow Alzheimer’s Discovered

Scientists have discovered the first drug of its kind that appears to slow the pace of mental decline in Alzheimer’s patients.

Solanezumab, developed by the American pharmaceutical company Eli Lilly, was shown to block memory loss in patients with a mild version of the disease, making it the first medicine ever to slow pace of damage to patients’ brains.

Existing drugs, such as Aricept, can manage only the symptoms of dementia by helping the dying brain cells function, but Solanezumab attacks the deformed proteins that build up in the brain during Alzheimer’s.

Dr Doug Brown, head of research at the Alzheimer’s Society, said: “Today’s findings strongly suggest that targeting people in the earliest stages of Alzheimer’s disease with these antibody treatments is the best way to slow or stop Alzheimer’s disease. These drugs are able to reduce the sticky plaques of amyloid that build up in the brain, and now we have seen the first hints that doing this early enough may slow disease progression.”

Should further trial results be positive, it could still be up to several years before the drug would become available on the NHS. Another phase-three trial is due to report in 2016 and then the drug would need to go through regulatory approval and would need to be shown to be sufficiently beneficial to patients.

Image credit: Ann Gordon

 

On & On We Grow – Introducing Liz Holdsworth

At Kinetica, we are always on the hunt for new talent to join our team and have recently had the pleasure of recruiting our newest member – Liz Holdsworth.

Liz has five years’ experience in the recruitment industry – four of which have been spent in the pharmaceutical and medical device markets.

Since joining Kinetica, Liz has focussed her efforts purely in the pharmaceutical sector, as this is where her strongest professional relationships have been built with clients and candidates alike.

With a genuine interest in the pharmaceutical industry, Liz can often be found pouring over articles and news items on the movements and progress of technology and science in this area.

Liz specialises in mid to senior level appointments, covering functions such as: Quality & Regulatory, Technical, R&D, Engineering & Manufacturing, Sales & Marketing, Operations Management and Continuous Improvement. She recruits both permanent and contract roles, and geographically covers the UK and Europe (Liz is also SECO registered for Swiss recruitment.)

Liz is a proven headhunter and a large majority of her work is exclusive or retained due to her impressive success rates. She has never placed a candidate in a role that didn’t prove fruitful, and can boast of 100% rebate-free track record.

If you are seeking an opportunity in the pharmaceutical sector, give Liz a call on 0113 261 71 81 or email liz.holdsworth@kinetica.co.uk or connect with her on LinkedIn here.

Liz Holdsworth

Could AstraZeneca’s New Drug Replace Chemotherapy?

The AstraZeneca drug MEDI4736 was revealed on Wednesday night as a “new great white hope” in the fight against cancer as it took centre stage in the British company’s battle against Pfizer‘s planned £63bn takeover.

It is this drug, developed in Cambridge and Maryland, that AstraZeneca chief executive, Pascal Soriot, was referring to when he warned MPs that an aggressive cost-cutting transaction could delay development and cost lives.

AstraZeneca’s head drug developer, Briggs Morrison, believes the drug could “hold the potential to shape the future of cancer treatment” and rake in annual sales of up to £3.9bn.

MEDI4736 works by stripping cancer cells of their “stealth cloak” so that the patient’s immune system can detect and kill tumours, and could replace chemotherapy in some cases.